Clinical trial

RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

NCT05933044

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2021-11-19

PhaseN/A

Study timeline

Study start (actual)2021-11-19Date precision: day

Registry last updated2023-09-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

MontrealQuebec, Canada1 VancouverBritish Columbia, Canada1 OttawaOntario, Canada1 CalgaryAlberta, Canada1 HalifaxNova Scotia, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05933044 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.